Company Overview of OptiNose AS
OptiNose AS, a drug delivery company, offers research and development for nasal drug and vaccine delivery devices for pharmaceutical and biotech companies. The company offers single and multi-use intranasal delivery devices for liquid and powder formulations. Its nasal drug delivery devices enable nasal administration of central nervous system, systemic, and topical nasal formulations; and breath actuated devices deliver intranasal drugs to targeted regions of the nasal cavity, including the sinuses and olfactory regions. OptiNose AS was founded in 2000 and is based in Oslo, Norway.
Austliveien 1 Røa
Founded in 2000
47 22 51 59 00
47 22 13 15 01
Key Executives for OptiNose AS
Chief Executive Officer and Director
Co-Founder and Chief Scientific Officer
Head of Device Development
Head of Regulatory and Quality Assurance
Compensation as of Fiscal Year 2013.
OptiNose AS Key Developments
Avanir and OptiNose Enter North American Licensing Agreement
Jul 15 13
Avanir Pharmaceuticals Inc. and OptiNose AS have entered into a North American licensing agreement for the development and commercialization of OptiNose's novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. Under the terms of the agreement, OptiNose received an upfront cash payment of $20 million and is eligible to receive certain shared development costs and up to an additional $90 million in total linked to the achievement of future clinical, regulatory and commercial milestones. In addition, if approved, Avanir will make tiered royalty payments based on net sales in North America.
Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for New Fast-Acting Investigational Product for the Treatment of Acute Migraine
Jul 2 13
Avanir Pharmaceuticals, Inc. and OptiNose AS announced that the companies have entered into an exclusive North American license agreement for the development and commercialization of OptiNose's novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first and only fast-acting, dry-powder nasal delivery form of sumatriptan. Under the terms of the agreement, OptiNose received an upfront cash payment of $20 million and is eligible to receive certain shared development costs and up to an additional $90 million in total linked to the achievement of future clinical, regulatory and commercial milestones. In addition, if approved, Avanir will make tiered royalty payments based on net sales in North America. Under the terms of the agreement, Avanir will assume responsibility for regulatory, manufacturing, supply-chain and commercialization activities for the investigational product, now named AVP-825. Both parties will work together on the remaining activities in support of the NDA submission. Avanir will begin preparing the NDA immediately and expects to file the application with the U.S. Food and Drug Administration by early calendar 2014.
OptiNose US Inc. to Present Data from Three Studies Featuring its Breath Powered Delivery Technology at the 2013 International Headache Congress
Jun 28 13
OptiNose US Inc. announced that it will present data from three studies featuring its Breath Powered delivery technology at the 2013 International Headache Congress from June 27 to 30 in Boston. Among the data being presented are results from the pivotal phase III TARGET study, which compares the efficacy and safety of the OptiNose Breath Powered nasal delivery device containing a low dose of sumatriptan powder to placebo in patients with moderate to severe migraine headaches. OptiNose's Breath Powered delivery technology is unique in that it uses the natural function of a user's breath to propel medications beyond the nasal valve into the deep, targeted areas of the nasal cavity more effectively, efficiently and consistently than current treatment approaches. A user exhales into the device, creating a naturally balanced closure of the soft palate and sealing off the nasal cavity completely. The exhaled breath carries medication from the device into one side of the nose through a sealing nosepiece. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air painlessly flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|